Skip to main content

Table 2 HER2 expression on circulating tumor cells and primary breast cancer

From: Minimal residual disease and circulating tumor cells in breast cancer

    

HER2+ CTCs/total CTCs (%)

 

Stage

HER2 PT

Enrichment/detection; CTC positive; CTC HER2 positive

CTC detection rate

HER2- PT

HER2+ PT

Reference

M0 and M1

FISH

EpCAM+ enrichment, C11, anti-CD45 (Her 81)

HER2 CTC: IF, 0, 1+, 2+, 3+, FISH

HER2+ CTCs: IF (3+), FISH HER2/CEP17 ≥2.0

NA

9/24 (37%)

11 of 15 (73%)

[74]

M0

IHC, FISH

Ficoll, immunomagnetic separation

ICC CK, HER2 (21N clone)

≥1 HER2+ CTC/50 ml

17/35 (49%)

12/24 (50%)

2/3 (67%)

[75]

M0

IHC, FISH

CellSearch®

≥1 CTC/7.5 ml

≥1 HER2 (3+) CTC/7.5 ml (HER2 IF: 0, 1+, 2+, 3+)

Before NAC: 46/213 (22%)

After NAC: 22/107 (11%)

8/37 (21%)

6/21 (28%)

[55]

IS and M0

IHC, FISH

CellSearch® ≥1 CTC/22.5 ml

≥1 HER2+ CTC/22.5 ml

HER2 Intensity CellSearch® ≥ 2.5

IS: 6/73 (8%)

M0:12/101(12%)

5/12 (41%)

5/5 (100%)

[59]

M0 and M1

IHC, FISH, CISH

CellSearch®

≥2 CTCs/7.5ml

≥50%HER2+ CTCs (HER2 IF: -, +)

40/66 (61%)

8/28 (29%)

7/12 (58%)

[76]

M1

IHC, FISH

AdnaTest®, RT-PCR

22/42 (52%)

5/17 (29%)

2/5 (40%)

[66]

M1

IHC, FISH

AdnaTest®, RT-PCR

CellSearch®

≥5 CTCs/7.5 ml

≥1 HER2 (3+) CTC/7.5 ml (HER2 IF: 0, 1+, 2+, 3+)

90/229 (30%)

122/245 (50%)

28/57 (49%)

25/76 (33%)

9/22 (41%)

18/31 (58%)

[42]

M1

IHC, FISH,

CellSearch® ≥1 CTC/7.5 ml

≥1 HER2+ CTC/7.5 ml (HER2 IF: -, +)

57/76 (75%)

6/42 (14%)

13/15 (87%)

[77]

M1

IHC, FISH

CellSearch® Profiling Kit, FISH for HER2

≥1 CTC/7.5 ml

HER2+ CTCs: FISH HER2/CEP17 ≥2.0

75/75 (100%)

10/30 (33%)

44/45 (98%)

[78]

M1

IHC, FISH

CellSearch® ≥1 CTC/7.5 ml

HER2 IF: 0, 1+, 2+, 3+

H-score ≥200 for HER2 IF

29/38 (76%)

3/18 (16%)

9/11 (82%)

[33]

  1. CISH, chromogenic in situ hybridization; CTC, circulating tumor cell; EpCAM, epithelial cell adhesion molecule; FISH, fluorescent in situ hybridization; ICC, immunocytochemistry; IF, immunofluoresence; IHC, immunohistochemistry; IS, ductal/lobular carcinoma in situ; M0, non-metastatic; M1, metastatic; NA, not available; NAC, neoadjuvant chemotherapy; PT, primary tumor; RT-PCR, reverse transcription PCR.